A phase I, open-label, multicenter study to assess safety, tolerability, PK and efficacy of MK-1084 as monotherapy and in combination with pembrolizumab in subjects with KRASG12C mutant advanced solid tumors 1084-001 Read more
Phase I/Iia, First-In-Human (FIH), Open-Label, Dose Escalation Trial With Expansion Cohorts To Evaluate Safety And Preliminary Efficacy Of CLDN6 CAR-T +/- CLDN6 RNA-LPX In Patients With CLDN6-Positive Relapsed Or Refractory Advanced Solid Tumors Read more
Phase I/II clinical trial of combination of OX40 and HDAC inhibitor in patients with Stage IV NSCLC Read more
The Effects And Mechanisms Of TNF-α/TNFR2 In Regulatory T Cells On Microenvironment And Progression In Gastric Cancer Read more
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations Read more
?A Phase 1/2, Dose Escalation And Expansion Study Of The Safety, Tolerability, And Anti-Tumor Activity Of BND-22 Administered Alone And In Combination With Pembrolizumab Or With Cetuximab In Patients With Advanced Solid Tumors Read more
Molecular profiling in patients with advanced lung or thymic cancer previously treated with immune checkpoint inhibitor therapy. Read more
A Phase 1, Multicenter, Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of TAB006, As Monotherapy And In Combination With Toripalimab, In Patients With Previously Treated, Advanced Malignancies Read more
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) Read more
